Pharmaceutical Commerce
OCTOBER 31, 2024
Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.
Bio Pharma Dive
OCTOBER 31, 2024
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding an IPO, its CEO said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 31, 2024
Reeves' budget promised investment for innovation and R&D with a view to "harnessing the full potential of the UK’s science base”.
Bio Pharma Dive
OCTOBER 31, 2024
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 31, 2024
The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was terminated.
Bio Pharma Dive
OCTOBER 31, 2024
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 31, 2024
Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on former director Jeff Shuren’s leadership.
Pharmaceutical Technology
OCTOBER 31, 2024
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
Bio Pharma Dive
OCTOBER 31, 2024
The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
Fierce Pharma
OCTOBER 31, 2024
Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. The drugmaker is "exploring opportunities to further improve productivity and efficiency," CEO Chris Boerner said Thursday.
pharmaphorum
OCTOBER 31, 2024
Effective language training for healthcare teams within the NHS is crucial for providing quality care and communication with diverse patient populations. Learn why it is essential for healthcare professionals.
Fierce Pharma
OCTOBER 31, 2024
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.
pharmaphorum
OCTOBER 31, 2024
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
OCTOBER 31, 2024
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.
pharmaphorum
OCTOBER 31, 2024
Our latest round-up of financings in the biotech sector features Alpha-9 Oncology, Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Therapeutics.
Fierce Pharma
OCTOBER 31, 2024
Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra. In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall Street's expectations and triggered a 16% surge in Madrigal's share price.
XTalks
OCTOBER 31, 2024
Paragonix Technologies, an innovator in organ transport and preservation solutions, has received US Food and Drug Administration (FDA) 510(k) clearance for its KidneyVault Portable Renal Perfusion System. This clearance allows the KidneyVault system to be used in the US to improve the quality of kidney preservation and ultimately improve outcomes for patients undergoing kidney transplants.
Fierce Pharma
OCTOBER 31, 2024
With U.S. | With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications.
Outsourcing Pharma
OCTOBER 31, 2024
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
pharmaphorum
OCTOBER 31, 2024
Compass Pathways will cut its headcount by 30% as it defers phase 3 readouts for its psychedelic therapy for treatment-resistant depression.
XTalks
OCTOBER 31, 2024
Each year, TIME Magazine curates its “Best Inventions” list to showcase innovations that push the boundaries of technology, healthcare and everyday living. For the 2024 list , TIME collected nominations from editors, correspondents and industry experts using an open submission platform. Each nomination was evaluated on criteria including originality, effectiveness, ambition and impact.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
OCTOBER 31, 2024
Septerna's protracted IPO on the Nasdaq has finally reached its conclusion, with the final amount raised by the GPCR-focused biotech above $331m
Fierce Pharma
OCTOBER 31, 2024
Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | The European Commission has fined Teva 462.6 million euros over allegations that the company “[abused] its dominant market position to delay competition” to Copaxone across multiple EU member states.
pharmaphorum
OCTOBER 31, 2024
Lexeo reveals "promising" early data for gene therapy for APOE4-associated Alzheimer's, but shares in the biotech fall.
Pharma Times
OCTOBER 31, 2024
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
OCTOBER 31, 2024
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Pharma Times
OCTOBER 31, 2024
The new Dementia Trials Accelerator is set to receive £20m of government funding
Drug Patent Watch
OCTOBER 31, 2024
The pharmaceutical industry has undergone significant transformations in recent years, driven by the COVID-19 pandemic and the subsequent need for rapid innovation and adaptation.
Fierce Pharma
OCTOBER 31, 2024
Author: Harietta Eleftherochorinou, Vice President, AI Strategy and Operations, IQVIA | We are entering a new era of AI in life sciences, where generative AI, conversational AI and AI agents are transforming day-to-day operations.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
59 
Let's personalize your content